BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 11, 2018 at 7:30 a.m. PT.
The live and replayed versions of the webcast will be available by visiting the “Investors” section of the Dynavax website at www.dynavax.com.
Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax’s lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
VP, Corporate Strategy & Communications